Fang Ying, Chen Yuning, Zhu Yichen, Tian Yanxin, Li Yan-Ruide, Yang Lili
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
STAR Protoc. 2025 May 2;6(2):103810. doi: 10.1016/j.xpro.2025.103810.
Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection. Here, we present a protocol for generating CAR-NKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. For complete details on the use and execution of this protocol, please refer to Li et al..
通用嵌合抗原受体工程化不变自然杀伤T细胞（CAR-NKT细胞）克服了同种异体嵌合抗原受体（CAR）-T细胞疗法的局限性，如移植物抗宿主病和同种异体排斥反应。在此，我们展示了一种从造血干细胞和祖细胞（HSPCs）生成CAR-NKT细胞的方案，随后进行无饲养层的体外分化。我们还概述了评估抗肿瘤疗效、安全性和同种异体排斥抗性的检测方法。有关本方案使用和执行的完整详细信息，请参考Li等人的研究。
